Strategic Insights: Unleashing the Potential of In Vitro Diagnostics in Your Business Portfolio

[Snehal Shaha]

Growth in the IVD market is driven by changing disease emergence patterns, the growing prevalence of chronic & infectious diseases, and increasing investments from private players. However, an unfavorable reimbursement scenario is expected to restrain the growth of this market during the forecast period.

The report In Vitro Diagnostics Market is projected to reach USD 138.4 billion by 2027 from USD 117.8 billion in 2022, at a CAGR of 3.3%.

Download PDF Brochure: - https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=703

Market Segmentation:-
The instruments segment is expected to reach the highest CAGR during the forecast period
Based on product & service, the IVD market is segmented into reagents & kits, instruments, services, and data management software. The instruments segment is to register the highest growth during the forecast period. The high growth in this market is attributed to the technological advancements in diagnostic analyzers. Market players are focused on innovating and launching IVD analyzers with inbuilt software and technology that aids in faster diagnostic results.

The hematology segment to register the highest growth during the forecast period
Based on technology, the IVD market is segmented into immunoassay/immunochemistry, clinical chemistry, molecular diagnostics, hematology, microbiology, coagulation & hemostasis, urinalysis, and other technologies. The hematology segment is to register the highest CAGR during the forecast period. The growth in this market is attributed to the increasing adoption of point-of-care (POC) testing for hematology diagnostics. Moreover, with the increased demand for hematology testing, market players are introducing innovative point-of-care testing solutions and instruments to aid in faster testing.

The oncology segment to register the highest growth during the forecast period
Based on application the IVD market is segmented into infectious diseases, diabetes, oncology, cardiology, drug testing/pharmacogenomics, HIV/AIDS, autoimmune diseases, nephrology, and other applications. The oncology segment is expected to register the highest CAGR during the forecast period. The increasing government and private funding initiatives for cancer research for early prevention and cure of cancer are expected to increase the adoption of IVD tests for the oncology segment.

The hospital laboratories segment accounted for the largest share of the in vitro diagnostics market
Based on end users, the IVD market is segmented into hospital laboratories, clinical laboratories, academic institutes, POC (point-of-care) testing centers, patients, and other end users. In 2021, hospital laboratories accounted for the largest share of the IVD market. With the rising prevalence of diseases and hospital admissions worldwide, hospital laboratories conduct the maximum number of IVD tests daily. IVD tests help physicians in decision-making and curating accurate treatment plans for their patients.

Regional Analysis:
Asia Pacific region to register the highest CAGR during the forecast period
The high growth rate of this segment can be attributed to the rising healthcare spending by a larger population base, healthcare infrastructure modernization, and the growing penetration of cutting-edge clinical laboratory technologies in the region. Moreover, government efforts to increase awareness about early disease detection, and regular health check-ups to further drive the market growth in the region.

Recent Developments:
• In November 2022, Thermo Fisher Scientific (US) launched the rapid RT-PCR Accula Flu A/Flu B Test designed to enable healthcare providers to detect and differentiate influenza A and B in about 30 minutes.
• In October 2022, Thermo Fisher Scientific (US) entered a definitive agreement to acquire The Binding Site Group, a global leader in specialty diagnostics. The Binding Site provides specialty diagnostic assays and instruments to improve the diagnosis and management of blood cancers and immune system disorders
• In September 2022, Sysmex Corporation (Japan) launched the UF-1500 Fully Automated Urine Particle Analyzer (UF-1500) for urine sediment testing. The UF-1500 inherits the high levels of functionality and usability of the UF-5000 Fully Automated Urine Particle Analyzer (UF-5000).
• In August 2022, Al-Futtaim Health (Dubai) and Abbott Laboratories (US) entered into a strategic partnership to improve the standards of advanced laboratory diagnostics in Dubai.
• In February 2022, Sysmex Corporation (Japan) opened a new subsidiary, Sysmex LLC, in Saudi Arabia. With this local subsidiary providing direct sales, Sysmex aims further to reinforce its sales and service structure in Saudi Arabia.
Request Sample Pages: -https://www.marketsandmarkets.com/requestsampleNew.asp?id=703

Top Key Players:
Prominent players in the in vitro diagnostics market include Roche Diagnostics (Switzerland), Danaher Corporation (US), Abbott Laboratories (US), Siemens Healthineers AG (Germany), and Thermo Fisher Scientific, Inc (US). Other players in this market include, Sysmex Corporation (Japan), Becton, Dickinson and Company (BD, US), Bio-Rad Laboratories, Inc. (US), QIAGEN N.V. (Netherlands), bioMérieux SA (France), Agilent Technologies, Inc. (US), DiaSorin S.p.A (Italy), Illumina, Inc. (US), Hologic, Inc. (US), Devyser (Sweden), PerkinElmer Inc. (US), Chembio Diagnostics, Inc. (US), SurModics, Inc. (US), Accelerate Diagnostics, Inc. (US), and Merck KGaA (Germany).